NCT07044466 Social Functioning in Opioid Use Disorder
| NCT ID | NCT07044466 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Medical University of South Carolina |
| Condition | Opioid Use Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 230 participants |
| Start Date | 2026-07-31 |
| Primary Completion | 2029-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 230 participants in total. It began in 2026-07-31 with a primary completion date of 2029-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Problems with social functioning are core to opioid use disorder (OUD), though specific, modifiable social functioning targets and how they relate to OUD treatment outcomes are poorly understood. This study will utilize both data from both patients with OUD and their concerned significant other (CSO) to examine associations between specific social functioning metrics and OUD treatment outcomes. Findings from this study will inform future precision-medicine approaches for people with OUD, a population in significant need of enhanced treatment approaches to combat opioid morbidity and mortality.
Eligibility Criteria
Inclusion Criteria: * Any sex or gender; any race or ethnicity; aged 18 years or older * Patient participants must meet DSM-5 diagnostic criteria for current (i.e., past 12 months) OUD (assessed via the Quick Structured Clinical Interview for DSM-5; Quick SCID) * Patient participants must be on buprenorphine, as prescribed by their provider, for no more than 4 weeks prior to study initiation * Patient participants must be in treatment at one of the following clinics in the Charleston area: MUSC's Center for Drug and Alcohol Programs (CDAP) clinic, MUSC's Bridge Clinic, the Charleston Center, Hope Integrative Medicine, or BHG Charleston * Concurrent substance use disorders (e.g., alcohol, cannabis) for the patient participant are acceptable, provided opioids are the patient participant's primary substance of choice * Patient participants must identify a CSO participant who consents to participation in the study as well Exclusion Criteria: * Moderate-to-severe opioid withdrawal as defined by a score of ≥21 on the Subjective Opioid Withdrawal Scale * Meeting DSM-5 criteria for a history of or current psychotic or bipolar disorders * Current suicidal or homicidal ideation and intent; participants who present a serious suicide risk are likely to require hospitalization during the study and they will be referred clinically * CSO participants meeting DSM-5 criteria for opioid use disorder or any other substance use disorder, excepting tobacco use disorder * Severe interpersonal violence in the past six months between the patient and the CSO, as defined by an adapted version of the Conflict Tactics Scaled Revised (CTS-2) * Pregnancy for patient participants * Prisoners, institutional individuals, and children will not be recruited for this study.
Contact & Investigator
Amber M Jarnecke, PhD
PRINCIPAL INVESTIGATOR
Medical University of South Carolina
Frequently Asked Questions
Who can join the NCT07044466 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Opioid Use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07044466 currently recruiting?
Yes, NCT07044466 is actively recruiting participants. Contact the research team at anderamb@musc.edu for enrollment information.
Where is the NCT07044466 trial being conducted?
This trial is being conducted at Charleston, United States.
Who is sponsoring the NCT07044466 clinical trial?
NCT07044466 is sponsored by Medical University of South Carolina. The principal investigator is Amber M Jarnecke, PhD at Medical University of South Carolina. The trial plans to enroll 230 participants.